Pre-made Bemarituzumab biosimilar ( Whole mAb, anti-FGFR2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-057
Anti-FGFR2 therapeutic antibody (Pre-made Bemarituzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Bemarituzumab (Amgen) is an investigational targeted antibody designed to block fibroblast growth factors from binding and activating FGFR2b. ... chemotherapy alone as first-line therapy for patients with FGFR2b-positive, non-HER2-positive advanced gastric or gastroesophageal cancers.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-FGFR2 therapeutic antibody (Pre-made Bemarituzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Five Prime Therapeutics;ZAI Lab|
|Conditions Active||Gastric cancer|
|Conditions Discontinued||Oesophageal cancer;Solid tumours|
|Development Tech||POTELLIGENT Technology|